PTC Therapeutics

PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2021 Financial Results

Thursday, October 14, 2021 - 1:58pm

SOUTH PLAINFIELD, N.J., Oct. 14, 2021 /PRNewswire/ --PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its third quarter 2021 financial results and provide an update on the company's business and outlook on Thursday, Oct. 28, at 4:30 p.m.

Key Points: 
  • SOUTH PLAINFIELD, N.J., Oct. 14, 2021 /PRNewswire/ --PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its third quarter 2021 financial results and provide an update on the company's business and outlook on Thursday, Oct. 28, at 4:30 p.m.
  • A live, listen-only webcast of the conference call can be accessed on the investor section of the PTC website at https://ir.ptcbio.com/events-presentations .
  • PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders.
  • To learn more about PTC, please visit us at www.ptcbio.com and follow us on Instagram, Facebook, Twitter, and LinkedIn.

PTC Therapeutics Celebrates Opening of Gene Therapy Manufacturing Facility

Thursday, October 14, 2021 - 1:30pm

SOUTH PLAINFIELD, N.J., Oct. 14, 2021 /PRNewswire/ -- PTC Therapeutics, Inc.(NASDAQ: PTCT) will host a ribbon-cutting ceremony to recognize the official opening of its new gene therapy manufacturing facility in Hopewell, N.J. today at 4 p.m.

Key Points: 
  • SOUTH PLAINFIELD, N.J., Oct. 14, 2021 /PRNewswire/ -- PTC Therapeutics, Inc.(NASDAQ: PTCT) will host a ribbon-cutting ceremony to recognize the official opening of its new gene therapy manufacturing facility in Hopewell, N.J. today at 4 p.m.
  • "We are committed to being an innovation-based company that brings the best therapies to patients with rare diseases," said Stuart W. Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics.
  • We have built our capabilities to both perform gene therapy research and to manufacture these biological products.
  • The Hopewell gene therapy manufacturing center complements PTC's existing operations at the Company's global headquarters in South Plainfield, N.J. and brings the total number of New Jersey-based employees to 625.

New Study Highlights the Value of Genetic Testing to Guide Clinical Management and Improve Outcomes for Epilepsy Patients

Saturday, September 25, 2021 - 5:15pm

This study underscores the importance of genetic testing for all people with epilepsy and supports the growing evidence that medical genetic testing can improve health outcomes and reduce healthcare costs.

Key Points: 
  • This study underscores the importance of genetic testing for all people with epilepsy and supports the growing evidence that medical genetic testing can improve health outcomes and reduce healthcare costs.
  • Notably, the research found that a change in clinical management once genetic results were received was reported by clinicians for nearly half of patients.
  • The full research presentation from Invitae included:
    Epilepsy genetic testing guides clinical management and helps improve patient outcomes.
  • This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the findings and implications of the study; and the value of genetic testing to guide clinical management and improve outcomes for epilepsy patients.

PTC Therapeutics to Host Conference Call to Discuss Results of PTC518 Phase 1 Study for Huntington's Disease Program

Monday, September 20, 2021 - 9:34pm

SOUTH PLAINFIELD, N.J., Sept. 20, 2021 /PRNewswire/ --PTC Therapeutics, Inc.(NASDAQ: PTCT) will host a conference call to discuss the positive results from the PTC518 Phase 1 healthy volunteer study.

Key Points: 
  • SOUTH PLAINFIELD, N.J., Sept. 20, 2021 /PRNewswire/ --PTC Therapeutics, Inc.(NASDAQ: PTCT) will host a conference call to discuss the positive results from the PTC518 Phase 1 healthy volunteer study.
  • During this call, the company will also provide an update on the PTC518 Phase 2 study, to be conducted in Huntington's disease patients, which PTC expects to initiate by the end of the year.
  • A live, listen-only audiocast will be available on the Events and Presentations page of the Investor section of PTC Therapeutics' website at www.ptcbio.com .
  • To learn more about PTC, please visit us at www.ptcbio.com and follow us on Instagram, Facebook, Twitter, and LinkedIn.

Aadi Bioscience Appoints Emma Reeve to its Board of Directors

Monday, September 13, 2021 - 1:00pm

LOS ANGELES, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (Aadi) (Nasdaq: AADI), a clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the appointment of Emma Reeve to its Board of Directors as Audit Committee Chair.

Key Points: 
  • LOS ANGELES, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (Aadi) (Nasdaq: AADI), a clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the appointment of Emma Reeve to its Board of Directors as Audit Committee Chair.
  • Most recently, Ms. Reeve was Chief Financial Officer of Constellation Pharmaceuticals, a development-stage oncology company,which went publicin2018 and raisedover $600 million in public and privatefinancings during her tenure.
  • We welcome Ms. Reeve to our Board at this pivotal time for Aadi as we are emerging post-IPO and transitioning to become a fully integrated biopharmaceutical company, stated Caley Castelein, M.D., Aadi Board Chairman.
  • Aadi Bioscience, Inc. (Aadi, The Company) cautions you that certain statements included in this press release that are not a description of historical facts are forward-looking statements.

PTC Therapeutics Recognizes 2021 STRIVE Awards Recipients for Initiatives Supporting Duchenne Patient Community

Tuesday, September 7, 2021 - 1:00pm

SOUTH PLAINFIELD, N.J., Sept. 7, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the three recipients who will receive funding through the company's STRIVE Awards program.

Key Points: 
  • SOUTH PLAINFIELD, N.J., Sept. 7, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the three recipients who will receive funding through the company's STRIVE Awards program.
  • The global STRIVE Awards program provides grants to non-profit organizations serving the Duchenne muscular dystrophy community.
  • "I am continually impressed with the passion and commitment of those working in and supporting the Duchenne community.
  • "The STRIVE Awards continue to provide organizations across the world with opportunities to improve outcomes for people living with Duchenne.

PTC Therapeutics to Participate at Upcoming Virtual Investor Conferences

Friday, August 27, 2021 - 1:00pm

SOUTH PLAINFIELD, N.J., Aug. 27, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the following conferences:

Key Points: 
  • SOUTH PLAINFIELD, N.J., Aug. 27, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the following conferences:
    Friday, September 10th at 11:00 a.m.
  • ET
    The presentation will be webcast live on the Events and Presentations page under the investor relations section of PTC Therapeutics' website at https://ir.ptcbio.com/events-presentations and will be archived for 30 days following the presentation.
  • It is recommended that users connect to PTC's website several minutes prior to the start of the webcast to ensure a timely connection.
  • PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders.

Adverum Appoints Global Regulatory Leader Jim Wang, Ph.D., as Senior Vice President, Head of Regulatory Affairs

Monday, August 23, 2021 - 2:00pm

Dr. Wang joins Adverum from PTC Therapeutics, where he served as vice president, global head of regulatory strategy, leading the planning and execution of worldwide regulatory activities across all therapeutic areas focusing on rare disease.

Key Points: 
  • Dr. Wang joins Adverum from PTC Therapeutics, where he served as vice president, global head of regulatory strategy, leading the planning and execution of worldwide regulatory activities across all therapeutic areas focusing on rare disease.
  • Previously, he worked with Spark Therapeutics, serving as vice president, head of regulatory affairs strategy.
  • Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases.
  • Adverum is evaluating its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of patients with wet age-related macular degeneration.

Zentalis Pharmaceuticals to Participate in the Wedbush PacGrow Healthcare Virtual Conference

Wednesday, August 4, 2021 - 12:00pm

NEW YORK and SAN DIEGO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that Anthony Sun, MD, Chairman and Chief Executive Officer of Zentalis, will participate in a panel discussion at the Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 11, 2021 at 10:20 a.m.

Key Points: 
  • NEW YORK and SAN DIEGO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that Anthony Sun, MD, Chairman and Chief Executive Officer of Zentalis, will participate in a panel discussion at the Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 11, 2021 at 10:20 a.m.
  • Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers.
  • Zentalis has licensed ZN-c3, ZN-c5 and ZN-d5 to its majority-owned joint venture, Zentera Therapeutics, to develop and commercialize these candidates in China.
  • This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2021 Financial Results

Thursday, July 15, 2021 - 1:00pm

SOUTH PLAINFIELD, N.J., July 15, 2021 /PRNewswire/ --PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its second quarter 2021 financial results and provide an update on the company's business and outlook on Thursday, July 29, 2021, at 4:30 p.m. (ET) after the closing of the market.

Key Points: 
  • SOUTH PLAINFIELD, N.J., July 15, 2021 /PRNewswire/ --PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its second quarter 2021 financial results and provide an update on the company's business and outlook on Thursday, July 29, 2021, at 4:30 p.m. (ET) after the closing of the market.
  • The call can be accessed by dialing (877) 303-9216 (domestic) or (973) 935-8152 (international) five minutes prior to the start of the call and providing the passcode 7064479.
  • A live, listen-only webcast of the conference call can be accessed on the investor relations section of the PTC website at https://ir.ptcbio.com/events-presentations .
  • PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders.